Log In
Print
BCIQ
Print
Print this Print this
 

LIPO-202

  Manage Alerts
Collapse Summary General Information
Company Neothetics Inc.
DescriptionSubcutaneous formulation of salmeterol, a long-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationBody Fat
Indication DetailsReduce subcutaneous abdominal fat
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today